Coronavirus COVID-19 Medical Science Plays

[JohnCM]

Co Diagnostics Inc (CODX)

13.47 +2.13 (18.78%)
Volume: 16,707,458 05/01/20 7:59:48 PM EDT

Outstanding Shares
27,438,701
03/22/2020

Opti Mist Friday, 05/01/20 12:54:52 PM
Re: None
Post # 2415 of 2419
I have owned INO, APT, and CODX over the past 3 months, several times selling one to switch to one of the others. My timing has not been great, but holding on to CODX has been a smart move as APT and INO are both down today. Strange that CODX is up 16% today while INO is down 16% today. I get the feeling that the short sellers are juggling these three stocks plus some others and see-sawing back and forth, driving them up and down. Someone is making a lot of money on the manipulation.

My problem is that if I sell CODX on its next high and move to one of the others on its next low, I lock in the tax payment on my gains, whereas if I keep one--that would currently be CODX I can ride it to the end and sell only what I need for cash. Or, if the company is bought by a big one--Johnson and Johnson or ?, then I can hold a larger, more stable stock into the future.

Probably no more switching for me. CODX is solid and should remain so for at least the next 18 months. Even if a vaccine is developed testing remains an important part of the world's future, and CODX is a leader in testing.

Opti

Co-Diagnostics, Inc Receives FDA Emergency Use Authorization for COVID-19 Test

April 06 2020 - 06:30AM
PR Newswire (US)

SALT LAKE CITY, April 6, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ Coronavirus COVID-19 Test has obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis of SARS-CoV-2.

The Company's test can be used by clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) to detect the presence of the virus that causes COVID-19, and is available for purchase from the Company's Utah-based ISO-13485:2016 certified facility.

Co-Diagnostics began offering its COVID-19 test to some U.S. CLIA labs in March 2020 as a result of the FDA's policy for diagnostic tests for COVID-19 during the current public health emergency. Previously, the Company had initiated sales of its CE-IVD test to the European Community, and to other global markets that accept a CE marking as valid regulatory approval following routine local product registration.

CEO of Co-Diagnostics Dwight Egan commented, "We believe that this authorization confirms the quality and performance of our COVID-19 test, and that it is a significant step in opening more doors and helping this test to reach an even wider audience.

Many experts agree that accessibility of widespread testing is an important element to 'flattening the curve' as U.S. cases of COVID-19 continue to rise, and that increased testing throughput is vital to achieve this objective. We look forward to continuing our goal of increasing the availability of advanced, high-throughput, and cost-effective COVID-19 testing solutions both close to home and across the globe."

The Co-Diagnostics Logix Smart™ Coronavirus COVID-19 Test uses the Company's patented CoPrimer™ technology to target the RdRp gene of the SARS-CoV-2 virus. The advanced nature of CoPrimers has allowed Co-Diagnostics to design a highly-specific, single-well PCR test, allowing higher throughput over tests that require multiple wells. Co-Diagnostics believes the lower cost of reagents in the Company's single-well test will help hospitals and laboratories to process more while paying less, benefiting healthcare providers and patients alike.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.